This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Latest papers
Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity.
Molecular therapy oncolytics · 2016
Latest funding
- $1,017,450
Supercharging cancer immunotherapy using clinician-controlled cytokine receptors
CIHR · 2025 · Nominated PI
- $3,051,528
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
CIHR · 2022 · Co-investigator
- $983,025
Deciphering the Hottest Immune Neighbourhoods in Ovarian Cancer to Advance Immunotherapy
CIHR · 2022 · Nominated PI
1 publications.
Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity.
Bourgeois-Daigneault MC, Roy DG, Falls T, Twumasi-Boateng K, St-Germain LE, Marguerie M, Garcia V, Selman M, Jennings VA, Pettigrew J, Amos S, Diallo JS, Nelson B, Bell JC
Supercharging cancer immunotherapy using clinician-controlled cytokine receptors
Principal investigators: Nelson, Brad H
Keywords: Cancer Immunotherapy; Cell Proliferation; Cell Viability; Cytokine Receptors; Cytokines; Genetic Engineering; Melanoma; Signal Transduction; Solid Tumours; T Cells
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
Principal investigators: Hay, Kevin A; Hawrysh, Terry A; Kekre, Natasha; Krueger, Joerg; Li, Amanda; Szwajcer, David
Keywords: Adoptive Immunotherapy; B-Cell Acute Lymphoblastic Leukemia; Cd22; Chimeric Antigen Receptor T Cells (Car-T)
Deciphering the Hottest Immune Neighbourhoods in Ovarian Cancer to Advance Immunotherapy
Principal investigators: Nelson, Brad H
Keywords: B Cells; Bioinformatics; Genomics; Immune Response; Immunotherapy; Myeloid Cells; Ovarian Cancer; Spatial Transcriptomics; T Cells; Tumour Microenvironment
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
Principal investigators: Hay, Kevin A; Hawrysh, Terry A; Kekre, Natasha; Krueger, Joerg; Li, Amanda; Szwajcer, David
Keywords: Adoptive Immunotherapy; B-Cell Acute Lymphoblastic Leukemia; Cd22; Chimeric Antigen Receptor T Cells (Car-T)
Podocalyxin's role in tumor invasion, metastasis, and immune evasion
Principal investigators: McNagny, Kelly M; Roskelley, Calvin D
Keywords: Breast Cancer; Cancer Therapy; Glycosylation; Immunolgy; Invasion; Metastasis; Ovarian/Fallopian Tube Cancer; Podocalyxin; Trangenic Mice; Tumor Stem Cells
A Phase I first-in-human trial of CLIC-2201, a VHH-CD22 CAR-T cell product for the treatment of relapsed/refractory CD22 positive B-cell non-Hodgkin lymphoma
Principal investigators: Hay, Kevin A; Kekre, Natasha
Keywords: Adoptive Immunotherapy; Car-T Cells; Chimeric Antigen Receptor; Diffuse Large B-Cell Lymphoma (Dlbl); Non-Hodgkin'S Lymphoma; Phase I Clinical Trial
Deciphering and harnessing the role of tumor-infiltrating B cells in anti-tumor immunity
Principal investigators: Banville, Allyson
Keywords: Antibodies; Antigens; B Cell Receptors; Cancer; Chimeric Antigen Receptor (Car) T Cell Therapy; Immunotherapy; Molecular Biology; Ovarian Cancer; Targeted Therapy; Tumor-Infiltrating B Cells
B-cell mediated immunity in high-grade serous ovarian cancer
Principal investigators: Laumont, Céline M
Keywords: B Cells; Immunotherapy; Mass Spectrometry; Ovarian Cancer; Single-Cell Sequencing; T Cells; Tumor Antigens; Tumor Microenvironment; Tumor-Infiltrating Lymphocytes
Mechanisms of B cell-mediated immunity in human cancer
Principal investigators: Nelson, Brad H
Keywords: Antibodies; B Cells; Cytokines; Genomics; Immunotherapy; Ovarian Cancer; Plasma Cells; Prognosis; T Cells; Tumour-Infiltrating Lymphocytes
Joint Meeting of the Canadian Cancer Immunotherapy Consortium and ImmunoBC 2018
Principal investigators: Nelson, Brad H
Keywords: Cancer Immunotherapy; Cell Therapy; Immune Modulation; Immunotherapy; Knowledge Transfer; Mentorship; National Meeting; Vaccination
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.